Vorapaxar in the Treatment of Cardiovascular Diseases
- 20 April 2020
- journal article
- research article
- Published by Taylor & Francis in Future Cardiology
- Vol. 16 (5) , 373-384
Abstract
Vorapaxar specifically and effectively inhibits protease activated receptor-1 and may reduce thrombin-mediated ischemic events without interfering primary hemostasis. In the TRA-2P-TIMI 50 trial, v...Keywords
This publication has 37 references indexed in Scilit:
- Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic StrokeStroke, 2013
- High-resolution crystal structure of human protease-activated receptor 1Nature, 2012
- Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialThe Lancet, 2012
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2012
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesNew England Journal of Medicine, 2012
- Vorapaxar: a novel protease-activated receptor-1 inhibitorExpert Opinion on Investigational Drugs, 2011
- Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 AntagonistDrug Metabolism and Disposition, 2011
- Combination Antithrombotic TherapiesCirculation, 2010
- Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet ActivityJournal of Medicinal Chemistry, 2008
- Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated ThrombosisCirculation, 2006